Gohealth Inc

GOCO remains in a Stage 4 decline with persistent lower highs and lower lows under declining EMAs. Relief rallies into the 9/20/50EMA and 50DMA quickly reject, and volume clusters on down moves confirm supply dominance. Short-term trend is down, with no exhaustion visible, making selling now into any bounce the optimal execution posture.

• ↑Q4 ’24 revenue $389 M (+41% YoY) driven by operational efficiency
• ↑CAC $501/submission (–27% YoY) reflects improved marketing strategies
• ↓Q3 ’25 revenue $95 M down as focus shifted to quality over volume